Alnylam Pharmaceuticals (ALNY) EBT (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of EBT data on file, last reported at $177.8 million in Q2 2026.

• Quarterly EBT rose 530.43% year-over-year to $177.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $766.3 million (up 321.28% YoY) and the FY2025 annual result came in at $323.2 million, up 185.63% from the prior year.
• EBT fell to $177.8 million in Q2 2026, from $221.7 million in the prior quarter.
• In the past five years, EBT ranged from a high of $280.6 million in Q3 2025 to a low of -$405.9 million in Q3 2022.
• A 5-year average of -$67.5 million and a median of -$86.1 million in 2024 frame the typical range for EBT.
• Annual changes were most pronounced in 2025 — EBT sank 269.92% — and 2026, when it jumped 9460.35%.
• Tracing ALNY's EBT over 5 years: stood at -$207.0 million in 2022, then soared by 33.49% to -$137.7 million in 2023, then plunged by 40.87% to -$194.0 million in 2024, then jumped by 144.47% to $86.3 million in 2025, then surged by 106.13% to $177.8 million in 2026.
• The last three EBT figures came in at $177.8 million (Q2 2026), $221.7 million (Q1 2026), and $86.3 million (Q4 2025), per Business Quant data.